Mach7 Technologies to beat analysts revenue forecast says MD Mike Lampron

Covid-19 will not affect the fiscal years revenue of medical technologies company Mach7 according to MD Mike Lampron.

Instead he told me, from his home in Oregon USA, that the company "Will definitely exceed $14 million dollars in revenue and should see some additional big deals coming through this fiscal year."

About Mach7 Technologies:

Mach7 Technologies (ASX:M7T) develops innovative data management solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7’s award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7’s sophisticated workflow tools, advanced clinical viewing and optimized vendor neutral archiving solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit Mach7 Technologies

Yesterday the company announced it has received another large purchase order for its software from its largest customer, Hospital Authority Hong Kong (HAHK), for A$4.8 million.

I caught up with Mike Lampron this morning and we discussed:

0.00 - Significance of Health Authority Hong Kong deal

1.45 - Thumbnail outline of what Mach7 technology does

4.01 - Will Mach7 play into push for telehealth?

5.57 - What is the finanancial health of the business?

7.37 - Mach7 will beat analysts revenue expectations

8.19 - What does the future hold for the rest of the year?

10.47 - How long are the deal lead times for Mach7?

You can jump direct to any of those questions by using the chapter markers on the play line.

DISCLAIMER AND IMPORTANT INFORMATION

I do not own shares in Mach7 at the time of writing this post. I also do not accept any payment from this or any other company I cover. Nor is my interview or blog in any way a recommendation and should not be seen as a form of financial advice. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.